肝硬化进展为肝细胞癌慢性乙型肝炎和丙型肝炎的分子机制

StephenW

Int J Mol Sci. 2019 Mar 18;20(6). pii: E1358. doi: 10.3390/ijms20061358.
Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.
Kanda T1, Goto T2, Hirotsu Y3, Moriyama M4, Omata M5,6.
Author information

1
    Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan. [email protected].
2
    Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506, Japan. [email protected].
3
    Genome Analysis Center, Yamanashi Central Hospital, Yamanashi 400-8506, Japan. [email protected].
4
    Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan. [email protected].
5
    Genome Analysis Center, Yamanashi Central Hospital, Yamanashi 400-8506, Japan. [email protected].
6
    The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. [email protected].

Abstract

Almost all patients with hepatocellular carcinoma (HCC), a major type of primary liver cancer, also have liver cirrhosis, the severity of which hampers effective treatment for HCC despite recent progress in the efficacy of anticancer drugs for advanced stages of HCC. Here, we review recent knowledge concerning the molecular mechanisms of liver cirrhosis and its progression to HCC from genetic and epigenomic points of view. Because ~70% of patients with HCC have hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection, we focused on HBV- and HCV-associated HCC. The literature suggests that genetic and epigenetic factors, such as microRNAs, play a role in liver cirrhosis and its progression to HCC, and that HBV- and HCV-encoded proteins appear to be involved in hepatocarcinogenesis. Further studies are needed to elucidate the mechanisms, including immune checkpoints and molecular targets of kinase inhibitors, associated with liver cirrhosis and its progression to HCC.
KEYWORDS:

HBV; HCV; cirrhosis; hepatocellular carcinoma

PMID:
    30889843
DOI:
    10.3390/ijms20061358

StephenW

Int J Mol Sci。 2019年3月18日; 20（6）。 pii：E1358。 doi：10.3390 / ijms20061358。
肝硬化进展为肝细胞癌慢性乙型肝炎和丙型肝炎的分子机制研究进展。
Kanda T1，Goto T2，Hirotsu Y3，Moriyama M4，Omata M5,6。
作者信息

1
    日本东京都板桥区Oyaguchi-kamicho 30-1日本大学医学部医学系消化内科和肝病科，173-8610，日本。 [email protected]。
2
    山梨县中央医院肺癌和呼吸疾病中心，日本山梨县富士见1-1-1富士见400-8506。 [email protected]。
3
    山梨县中心医院基因组分析中心，日本山梨县400-8506。 [email protected]。
4
    日本东京都板桥区Oyaguchi-kamicho 30-1日本大学医学部医学系消化内科和肝病科，173-8610，日本。 [email protected]。
五
    山梨县中心医院基因组分析中心，日本山梨县400-8506。 [email protected]。
6
    东京大学，东京都文京区本乡7-3-1，东京113-8655。 [email protected]。

抽象

几乎所有肝细胞癌（HCC），一种主要类型的原发性肝癌患者，也患有肝硬化，尽管最近在抗癌药物治疗晚期HCC的疗效方面取得了进展，但其严重程度阻碍了对HCC的有效治疗。在这里，我们从遗传和表观基因组学的角度回顾最近关于肝硬化分子机制及其进展为HCC的知识。因为约70％的HCC患者患有乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HCV）感染，我们专注于HBV和HCV相关的HCC。文献表明，遗传和表观遗传因素，如microRNA，在肝硬化及其进展为HCC中发挥作用，HBV和HCV编码的蛋白似乎与肝癌发生有关。需要进一步的研究来阐明与肝硬化相关的激酶抑制剂的免疫检查点和分子靶点及其进展为HCC的机制。
关键词：

HBV; HCV;肝硬化;肝细胞癌

结论：
    30889843
DOI：
    10.3390 / ijms20061358

StephenW

https://www.mdpi.com/1422-0067/20/6/1358/pdf